nach oben

Archives of Gynecology and Obstetrics

Erschienen in:

01.07.2012 | Maternal-Fetal Medicine

Pre-eclampsia following chemotherapy for breast cancer during pregnancy: case report and review of the literature

verfasst von: L. Massey Skatulla, S. Loibl, B. Schauf, T. Müller

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

There has been some discussion about the effect of antineoplastic agents on the trophoblast, and whether this is associated with abnormal placental function such as an increased risk of pre-eclampsia/eclampsia. We discuss a possible causal relationship between chemotherapy for breast cancer during pregnancy and the development of pre-eclampsia based on the occurrence of both in a recent pregnancy.

Methods

We report the case of a 34-year-old gravida 4, para 1 with unilateral ductal invasive breast cancer, treated by surgery and subsequent chemotherapy during pregnancy. At 36 + 2 weeks of gestation a growth restricted male infant (1,680 g, <5th percentile) was born by urgent caesarean section because of acute pre-eclampsia, pathologic CTG and umbilical end-diastolic reverse flow. This case is reported in detail, and literature and databases reviewed.

Results

So far there have been no reports suggesting an increased risk of pre-eclampsia following chemotherapy for breast cancer in pregnancy from the second trimester onwards, and the most probable is an accidental occurrence from pre-eclampsia and chemotherapy.

Conclusions

Whenever possible, pregnant patients with breast cancer should receive the same treatment as those who are not pregnant. Should chemotherapy for breast cancer be indicated in pregnancy from the second trimester onwards only, contraindications would be other risks for pre-eclampsia and intrauterine growth restriction, such as smoking and gestational diabetes.

Stensheim H, Møller B, van Dijk T, Fosså SD (2009) Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registry-based cohort study. J Clin Oncol 27:45–51PubMedCrossRef

Walton JR, Prasad MR (2011) Obstetric and neonatal outcomes of cancer treated during pregnancy. Clin Obstet Gynecol 54:567–573PubMedCrossRef

Doll D, Ringenberg Q, Yarbro J (1988) Management of cancer in pregnancy. Arch Intern Med 148:2058–2064PubMedCrossRef

Brewer M, Kueck A, Runowicz CD (2011) Chemotherapy in pregnancy. Clin Obstet Gynecol 54:602–618PubMedCrossRef

Zemlickis D, Lishhner M, Degendorfer P, Panzarella T, Sutcliffe SB, Koren G (1992) Fetal outcome after in utero exposure to cancer chemotherapy. Arch Intern Med 152:573–657PubMedCrossRef

Ring AE, Smith IE, Jones A, Shannon C, Galani E, Ellis PA (2005) Chemotherapy for breast cancer during pregnancy: an 18-year experience from five London teaching hospitals. J Clin Oncol 23:4192–4197PubMedCrossRef

Reynoso EE, Shepherd FA, Messner HA, Farquharson HA, Garvey MB, Baker MA (1987) Acute leukemia study group experience with long-term follow-up of children exposed in utero to chemotherapeutic agents. J Clin Oncol 5:1098–1106PubMed

Zuazu J, Julia A, Sierra J, Valentin MG, Coma A, Sanz MA, Batlle J, Flores A (1991) Pregnancy outcome in hematologic malignancies. Cancer 67:703–709PubMedCrossRef

Müller T, Hofmann J, Steck T (1996) Eclampsia after polychemotherapy for nodal-positive breast cancer during pregnancy. Eur J Obstet Gynecol Reprod Biol 67:197–198PubMedCrossRef

10.

Mignini L (2007) Antiplatelet agents for preventing and treating pre-eclampsia, WHO RHL commentary Geneva

11.

Villar J, Abalos E, Nardin JM, Merialdi M, Carroli G (2004) Strategies to prevent and treat preeclampsia: evidence from randomized controlled trials. Semin Nephrol 24:607–615PubMed

12.

Wang A, Rana S, Karumanchi SA (2009) Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology (Bethesda) 24:147–158CrossRef

13.

Jauniaux E, Poston L, Burton GJ (2006) Placental-related diseases of pregnancy: involvement of oxidative stress and implications in human evolution. Hum Reprod Update 12:747–755PubMedCrossRef

14.

Hung TH, Charnock-Jones DS, Skepper JN, Burton GJ (2004) Secretion of tumor necrosis factor-alpha from human placental tissues induced by hypoxia-reoxygenation causes endothelial activation in vitro: a potential mediator of the inflammatory response in preeclampsia. Am J Pathol 164:1049–1061PubMedCrossRef

15.

Vanderlie J, Venardos K, Clifton VL, Gude NM, Clarke FM, Perkins AV (2005) Increased biological oxidation and reduced anti-oxidant enzyme activity in pre-eclamptic placentae. Placenta 26:53–58CrossRef

16.

Poston L, Igosheva N, Mistry HD, Seed PT, Shennan AH, Rana S, Karumanchi SA, Chappell LC (2011) Role of oxidative stress and antioxidant supplementation in pregnancy disorders. Am J Clin Nutr 94:1980–1985CrossRef

17.

Mutter WP, Karumanchi SA (2008) Molecular mechanisms of preeclampsia. Microvasc Res 75:1–8PubMedCrossRef

18.

Burton GJ, Woods AW, Jauniaux E, Kingdom JC (2009) Rheological and physiological consequenses of conversion of the maternal spiral arteries for uteroplazental blood flow during human pregnancy. Placenta 30:473–482PubMedCrossRef

19.

Goldman-Wohl D, Yagel S (2002) Regulation of trophoblast invasion: from normal implantation to pre-eclampsia. Mol Cell Endocrinol 187:233–238PubMedCrossRef

20.

Zhou Y, Damsky CH, Fisher SJ (1997) Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome? J Clin Invest 99:2152–2164PubMedCrossRef

21.

Lam C, Lim KH, Karumanchi SA (2005) Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension 46:1077–1085PubMedCrossRef

22.

Hawfield A, Bl Freedman (2009) Pre-eclampsia: the pivotal role of the placenta in its pathophysiology and markers for early detection. Ther Adv Cardiovasc Dis 3:65–73PubMedCrossRef

23.

Lyall F, Myatt L (2002) The role of the placenta in pre-eclampsia: a workshop report. Placenta 23:142–145CrossRef

24.

Dechanet C, Fort A, Barbero-Camps E, Dechaud H, Richard S, Virsolvy A (2011) Endothelin-dependent vasoconstriction in human uterine artery: application to preeclampsia. PLoS ONE 26:e16540CrossRef

25.

Agarwal I, Karumanchi SA (2011) Preeclampsia and the anti-angiogenic state. Pregnancy Hypertens 1:17–21PubMedCrossRef

26.

Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111:649–658PubMed

27.

Levine RJ, Lam C, Qian C et al (2006) Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 355:992–1005PubMedCrossRef

28.

Levine RJ, Maynard SE, Qian C et al (2004) Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350:672–683PubMedCrossRef

29.

Lu F, Longo M, Tamayo E, Maner W, Al-Hendy A, Anderson GD, Hankins GDV, Saade GR (2007) The effect of over-expression of sFlt-1 on blood pressure and the occurence of other manifestations of preeclampsia in unrestrained conscious pregnant mice. Am J Obstet Gynecol 196(396):e1–e7

30.

Li Z, Zhang Y, Ying Ma J, Kapoun AM, Shao Q, Kerr I, Lam A, O`Young G, Sannajust F, Stathis P, Schreiner G, Karumanchi SA, Protter AA, Pollitt NS (2007) Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension 50:686–692PubMedCrossRef

31.

Nagamatsu T, Fujii T, Kusumi M, Zou L, Yamashita T, Osuga Y, Momoeda M, Kozuma S, Taketani Y (2004) Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia. Endocrinology 145:4838–4845PubMedCrossRef

32.

LaMarca BD, Gilbert G, Granger JP (2008) Recent progress toward the understanding of the pathophysiology of hypertension during preeclampsia. Hypertension 51:982–988PubMedCrossRef

33.

LaMarca BD, Alexander BT, Gilbert JS, Ryan MJ, Sedeek M, Murphy SR, Granger JP (2008) Pathophysiology of hypertension in response to placental ischemia during pregnancy: a central role for endothelin? Gend Med 5:133–138CrossRef

34.

Wang Y, Walsh SW, Guo J, Zhang J (1991) The imbalance between thromboxane and prostacyclin in preeclampsia is associated with an imbalance between lipid peroxides and vitamin E in maternal blood. Am J Obstet Gynecol 165:1695–1700PubMed

35.

Schauf B, Becker S, Abele H, Klever T, Wallwiener D, Aydeniz B (2005) Effect of magnesium on red blood cell deformability in pregnancy. Hypertens Pregnancy 24:17–27PubMed

36.

Schauf B, Lang U, Stute P, Schneider ST, Dietz K, Aydeniz B, Wallwiener D (2002) Reduced red-blood-cell deformability, an indicator for high fetal or maternal risk, is found in Preeklampsia and IUGR. Hypertension in pregnancy 21:147–160PubMedCrossRef

37.

Carr DB, Epplein M, Johnson CO, Easterling TR, Critchlow CW (2005) A sister’s risk: family history as a predictor of preeclampsia. Am J Obstet Gynecol 193:965–972PubMedCrossRef

38.

Mutze S, Rudnik-Schoneborn S, Zerres K, Rath W (2008) Genes and the preeclampsia syndrome. J Perinat Med 36:38–58PubMedCrossRef

39.

Tuohy JF, James DK (1992) Pre-eclampsia and trisomy 13. Br J Obstet Gynaecol 99:891–894PubMedCrossRef

40.

Zarkovic N (2005) Antioxidatien in der Pravention und Chemotherapie von Tumoren. In: Siems W, Kramer K, Grune T (eds) Oxidativer Stress und Pharmaka. Govi-Verlag, Eschborn, pp 159–174

41.

Odom LD, Plouffe L Jr, Butler WJ (1990) 5-fluorouracil exposure during the period of conception: report on two cases. Am J Obstet Gynecol 163:76–77PubMed

42.

Kopelman JN, Miyazawa K (1990) Inadvertent 5-fluorouracil treatment in early pregnancy: a report of three cases. Reprod Toxicol 4:233–235PubMedCrossRef

43.

Gaillard B, Leng JJ, Grellet J, Ducint D, Saux MC (1995) Transplacental passage of epirubicin. J Gynecol Obstet Biol Reprod (Paris) 24:63–68

44.

Scialli AR, Waterhouse TB, Desesso JM, Rahman A, Goeringer GC (1997) Protective effect of liposome encapsulation on paclitaxel developmental toxicity in the rat. Teratology 56:305–310PubMedCrossRef

45.

Avilés A, Neri N (2001) Hematological malignancies and pregnancy: a final report of 84 children who received chemotherapy in utero. Clin Lymphoma 2:173–177PubMedCrossRef

46.

Loibl S, Amant F, Kaufmann M, Ring A, Han S, Giermek J, Fehm T, Bontenbal M, Heinrigs M, Lenhard M, Scherr I, Mehta K, von Minckwitz G (2010) 1313 patients with breast cancer during pregnancy: results from a prospective and retrospective registry (GBG-20/BIG02-03). Cancer Res 70:91CrossRef

47.

Loibl S (2010) Mammakarzinom in der Schwangerschaft. Interdisziplinäres Vorgehen und Behandlungsoptionen. Gynäkologie 6:8–12

48.

Loibl S (2008) New therapeutic options for breast cancer during pregnancy. Breast Care 3:171–176PubMedCrossRef

49.

Amant F, Deckers S, Van Calsteren K, Loibl S, Halaska M, Brepoels L, Beijnen J, Cardoso F, Gentilini O, Lagae L, Mir O, Neven P, Ottevanger N, Pans S, Peccatori F, Rouzier R, Senn HJ, Struikmans H, Christiaens MR, Cameron D, Du Bois A (2010) Breast cancer in pregnancy: recommendations of an international consensus meeting. Eur J Cancer 46:3158–3168PubMedCrossRef

Titel: Pre-eclampsia following chemotherapy for breast cancer during pregnancy: case report and review of the literature
verfasst von: L. Massey Skatulla
S. Loibl
B. Schauf
T. Müller
Publikationsdatum: 01.07.2012
Verlag: Springer-Verlag
Erschienen in: Archives of Gynecology and Obstetrics / Ausgabe 1/2012
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-012-2257-y

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Pre-eclampsia following chemotherapy for breast cancer during pregnancy: case report and review of the literature

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

ICI-Therapie in der Schwangerschaft wird gut toleriert

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

Update Gynäkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2012

Using a titanium-coated polypropylene mesh (TiLOOP® Bra) for implant-based breast reconstruction: case report and histological analysis

Adenosine deaminase activity in patients with ovarian neoplasms

Maternal underweight status and association with preterm contractions

Maternal request: a reason for rising rates of cesarean section?

The use of porcine acellular dermal matrix in silicone implant-based breast reconstruction

Erratum to: c-Kit proto-oncogene expression in endometrial hyperplasia and endometrial cancer

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

ICI-Therapie in der Schwangerschaft wird gut toleriert

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

Update Gynäkologie